CRISPR Beneish M Score

CRSP
 Stock
  

USD 66.15  0.75  1.12%   

This module uses fundamental data of CRISPR Therapeutics to approximate the value of its Beneish M Score. CRISPR Therapeutics M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Continue to CRISPR Therapeutics Piotroski F Score and CRISPR Therapeutics Altman Z Score analysis.
  
Refresh
As of 28th of June 2022, Total Debt is likely to grow to about 242.8 M. Also, Debt Current is likely to grow to about 12.6 M. CRISPR Therapeutics Enterprise Value over EBIT is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Enterprise Value over EBIT of 13.00. As of 28th of June 2022, Enterprise Value over EBITDA is likely to grow to 13.50, while Current Ratio is likely to drop 19.30.
At this time, it appears that CRISPR Therapeutics is an unlikely manipulator. The earnings manipulation may begin if CRISPR Therapeutics' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by CRISPR Therapeutics executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of CRISPR Therapeutics' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-2.76
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables0.95Focus
Asset Quality0.85Focus
Expense Coverage0.74Focus
Gross Margin Strengs0.99Focus
Accruals Factor0.74Focus
Depreciation Resistance1.0Focus
Net Sales Growth1.08Focus
Financial Leverage Condition1.0Focus

CRISPR Therapeutics Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if CRISPR Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Revenues987.2 M915 M
Significantly Up
Increasing
Slightly volatile
Selling General and Administrative Expense82.2 M102.8 M
Significantly Down
Increasing
Slightly volatile
Net Cash Flow from Operations581.5 M539 M
Significantly Up
Increasing
Slightly volatile
Depreciation Amortization and Accretion19.4 M18 M
Significantly Up
Increasing
Slightly volatile
Total AssetsB2.8 B
Significantly Up
Increasing
Slightly volatile
Investments1.3 B1.5 B
Significantly Down
Increasing
Slightly volatile
Investments Current1.3 B1.5 B
Significantly Down
Increasing
Slightly volatile
Property Plant and Equipment Net336.7 M312 M
Significantly Up
Increasing
Slightly volatile
Trade and Non Trade Receivables313 K305 K
Fairly Up
Decreasing
Very volatile
Total Liabilities380.2 M352.4 M
Significantly Up
Increasing
Slightly volatile
Current Assets2.6 B2.4 B
Significantly Up
Increasing
Slightly volatile
Assets Non Current360.8 M334.4 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities129.3 M119.9 M
Significantly Up
Increasing
Slightly volatile
Liabilities Non Current250.9 M232.5 M
Significantly Up
Increasing
Slightly volatile
Total Debt242.8 M225 M
Significantly Up
Increasing
Slightly volatile
Debt Current12.6 M12.2 M
Sufficiently Up
Increasing
Slightly volatile
Debt Non Current229.7 M212.9 M
Significantly Up
Increasing
Slightly volatile
Operating Income403 M373.5 M
Significantly Up
Increasing
Stable
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile

CRISPR Therapeutics Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between CRISPR Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards CRISPR Therapeutics in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find CRISPR Therapeutics' degree of accounting gimmicks and manipulations.

About CRISPR Therapeutics Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation Amortization and Accretion

19.37 Million

Share
CRISPR Therapeutics Depreciation Amortization and Accretion is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Depreciation Amortization and Accretion of 17.95 Million

CRISPR Therapeutics Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as CRISPR Therapeutics. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
201720182019202020212022 (projected)
Trade and Non Trade Receivables2.63 M88 K99 K144 K305 K313.03 K
Revenues41 M3.12 M289.59 M719 K914.96 M987.2 M
Total Assets271.35 M489.02 M1.07 B1.83 B2.75 B2.97 B
Current Assets248.38 M466.39 M987.55 M1.72 B2.42 B2.61 B
Assets Non Current22.96 M22.62 M79.2 M111.35 M334.36 M360.76 M
Property Plant and Equipment Net18.86 M18.5 M72.83 M93.03 M312.04 M336.67 M
Depreciation Amortization and Accretion3.02 M3.52 M4.72 M9.18 M17.95 M19.37 M
Selling General and Administrative Expense35.84 M48.29 M63.49 M88.21 M102.8 M82.2 M
Total Liabilities83.51 M96.82 M127.33 M163.73 M352.42 M380.24 M
Current Liabilities14.51 M27.75 M57.11 M94.26 M119.88 M129.35 M
Liabilities Non Current69 M69.08 M70.22 M69.47 M232.53 M250.89 M
Operating Income(64.65 M)(158.94 M)46.74 M(354.44 M)373.53 M403.02 M
Net Cash Flow from Operations(70.09 M)(96.24 M)56.68 M(238.37 M)538.97 M581.52 M

About CRISPR Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze CRISPR Therapeutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CRISPR Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CRISPR Therapeutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. CRISPR Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 473 people.

CRISPR Therapeutics Investors Sentiment

The influence of CRISPR Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in CRISPR. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CRISPR Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CRISPR Therapeutics' short interest history, or implied volatility extrapolated from CRISPR Therapeutics options trading.

Current Sentiment - CRSP

CRISPR Therapeutics Investor Sentiment

Most of Macroaxis users are currently bullish on CRISPR Therapeutics AG. What is your opinion about investing in CRISPR Therapeutics AG? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Pair Trading with CRISPR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CRISPR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

CRISPR Therapeutics Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to CRISPR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CRISPR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CRISPR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CRISPR Therapeutics AG to buy it.
The correlation of CRISPR Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CRISPR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CRISPR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CRISPR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to CRISPR Therapeutics Piotroski F Score and CRISPR Therapeutics Altman Z Score analysis. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Commodity Channel Index module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.